BONESUPPORT initiates a SEK 100 million share buyback program
The Board authorizes the repurchase to optimize capital structure and increase shareholder value through potential cancellations by October 2026.
See the latest news and media coverage for BONESUPPORT. We track all announcements, press releases, and industry mentions in real time, all in one place.
Scandinavian orthobiologics company
bonesupport.comLast updated
In short: BONESUPPORT delivered strong financial growth through 2025 and 2026, despite a delay in its FDA submission for CERAMENT V.
The Board authorizes the repurchase to optimize capital structure and increase shareholder value through potential cancellations by October 2026.
The final rule assigns CERAMENT G to highest reimbursing DRGs for complex orthopedic infections, effective October 1, 2026.
The board resolved to acquire up to 373,320 shares for SEK 100 million under LTI 2026.
Net sales rose 14% to SEK 324.0 million. US growth was 16%. Adjusted operating result reached SEK 84.9 million.
Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. For reasons most of us will hope to never find...
The medical technology company Bonesupport has signed a distribution partnership with the US-based Stryker for Australia and New Zealand. In the fourth quarter of...
Detailed price information for Bonesupport Holding Ab (BOEUF) from The Globe and Mail including charting and trades.
BONESUPPORT delivered strong Q3 2025 results with net sales of SEK 294 million, up 24% YoY (34% at constant currency). Adjusted operating margin reached 27...
Track BONESUPPORT and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to BONESUPPORT and other trending companies.